Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks.


Journal

Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895

Informations de publication

Date de publication:
11 2021
Historique:
received: 09 09 2020
accepted: 24 02 2021
revised: 03 02 2021
pubmed: 15 3 2021
medline: 31 12 2021
entrez: 14 3 2021
Statut: ppublish

Résumé

Acute lymphoblastic leukemia (ALL) is a hematopoietic malignancy comprised of molecular subtypes largely characterized by aneuploidy or recurring chromosomal rearrangements. Despite extensive information on the ALL transcriptome and methylome, there is limited understanding of the ALL chromatin landscape. We therefore mapped accessible chromatin in 24 primary ALL cell biospecimens comprising three common molecular subtypes (DUX4/ERG, ETV6-RUNX1 and hyperdiploid) from patients treated at St. Jude Children's Research Hospital. Our findings highlight extensive chromatin reprogramming in ALL, including the identification ALL subtype-specific chromatin landscapes that are additionally modulated by genetic variation. Chromatin accessibility differences between ALL and normal B-cells implicate the activation of B-cell repressed chromatin domains and detail the disruption of normal B-cell development in ALL. Among ALL subtypes, we uncovered roles for basic helix-loop-helix, homeodomain and activator protein 1 transcription factors in promoting subtype-specific chromatin accessibility and distinct gene regulatory networks. In addition to chromatin subtype-specificity, we further identified over 3500 DNA sequence variants that alter the ALL chromatin landscape and contribute to inter-individual variability in chromatin accessibility. Collectively, our data suggest that subtype-specific chromatin landscapes and gene regulatory networks impact ALL biology and contribute to transcriptomic differences among ALL subtypes.

Identifiants

pubmed: 33714976
doi: 10.1038/s41375-021-01209-1
pii: 10.1038/s41375-021-01209-1
pmc: PMC8435544
mid: NIHMS1713775
doi:

Substances chimiques

Chromatin 0
Transcription Factors 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3078-3091

Subventions

Organisme : NCI NIH HHS
ID : P30 CA021765
Pays : United States
Organisme : NIGMS NIH HHS
ID : P50 GM115279
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA036401
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA234490
Pays : United States

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Références

Moriyama T, Relling MV, Yang JJ. Inherited genetic variation in childhood acute lymphoblastic leukemia. Blood. 2015;125:3988–95.
pubmed: 25999454 pmcid: 4481591 doi: 10.1182/blood-2014-12-580001
Mullighan CG. Molecular genetics of B-precursor acute lymphoblastic leukemia. J Clin Investig. 2012;122:3407–15.
pubmed: 23023711 pmcid: 3461902 doi: 10.1172/JCI61203
Lilljebjorn H, Henningsson R, Hyrenius-Wittsten A, Olsson L, Orsmark-Pietras C, von Palffy S, et al. Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia. Nat Commun. 2016;7:11790.
pubmed: 27265895 pmcid: 4897744 doi: 10.1038/ncomms11790
Andersson A, Olofsson T, Lindgren D, Nilsson B, Ritz C, Eden P, et al. Molecular signatures in childhood acute leukemia and their correlations to expression patterns in normal hematopoietic subpopulations. Proc Natl Acad Sci USA. 2005;102:19069–74.
pubmed: 16354839 pmcid: 1323166 doi: 10.1073/pnas.0506637102
Figueroa ME, Chen SC, Andersson AK, Phillips LA, Li Y, Sotzen J, et al. Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia. J Clin Investig. 2013;123:3099–111.
pubmed: 23921123 pmcid: 3696550 doi: 10.1172/JCI66203
Almamun M, Levinson BT, van Swaay AC, Johnson NT, McKay SD, Arthur GL, et al. Integrated methylome and transcriptome analysis reveals novel regulatory elements in pediatric acute lymphoblastic leukemia. Epigenetics. 2015;10:882–90.
pubmed: 26308964 pmcid: 4622668 doi: 10.1080/15592294.2015.1078050
Shlyueva D, Stampfel G, Stark A. Transcriptional enhancers: from properties to genome-wide predictions. Nat Rev Genet. 2014;15:272–86.
pubmed: 24614317 doi: 10.1038/nrg3682
Buenrostro JD, Giresi PG, Zaba LC, Chang HY, Greenleaf WJ. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat Methods. 2013;10:1213–8.
pubmed: 24097267 pmcid: 3959825 doi: 10.1038/nmeth.2688
Corces MR, Buenrostro JD, Wu B, Greenside PG, Chan SM, Koenig JL, et al. Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution. Nat Genet. 2016;48:1193–203.
pubmed: 27526324 pmcid: 5042844 doi: 10.1038/ng.3646
Iacobucci I, Mullighan CG. Genetic Basis of Acute Lymphoblastic Leukemia. J Clin Oncol. 2017;35:975–83.
pubmed: 28297628 pmcid: 5455679 doi: 10.1200/JCO.2016.70.7836
Shurtleff SA, Buijs A, Behm FG, Rubnitz JE, Raimondi SC, Hancock ML, et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia. 1995;9:1985–9.
pubmed: 8609706
Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 2002;1:133–43.
pubmed: 12086872 doi: 10.1016/S1535-6108(02)00032-6
Gabriels J, Beckers MC, Ding H, De Vriese A, Plaisance S, van der Maarel SM, et al. Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element. Gene. 1999;236:25–32.
pubmed: 10433963 doi: 10.1016/S0378-1119(99)00267-X
Zhang J, McCastlain K, Yoshihara H, Xu B, Chang Y, Churchman ML, et al. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat Genet. 2016;48:1481–9.
pubmed: 27776115 pmcid: 5144107 doi: 10.1038/ng.3691
Paulsson K, Forestier E, Lilljebjorn H, Heldrup J, Behrendtz M, Young BD, et al. Genetic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 2010;107:21719–24.
pubmed: 21098271 pmcid: 3003126 doi: 10.1073/pnas.1006981107
Savic D, Ramaker RC, Roberts BS, Dean EC, Burwell TC, Meadows SK, et al. Distinct gene regulatory programs define the inhibitory effects of liver X receptors and PPARG on cancer cell proliferation. Genome Med. 2016;8:74.
pubmed: 27401066 pmcid: 4940857 doi: 10.1186/s13073-016-0328-6
Calderon D, Nguyen MLT, Mezger A, Kathiria A, Muller F, Nguyen V, et al. Landscape of stimulation-responsive chromatin across diverse human immune cells. Nat Genet. 2019;51:1494–505.
pubmed: 31570894 pmcid: 6858557 doi: 10.1038/s41588-019-0505-9
Paugh SW, Bonten EJ, Savic D, Ramsey LB, Thierfelder WE, Gurung P, et al. NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nat Genet. 2015;47:607–14.
pubmed: 25938942 pmcid: 4449308 doi: 10.1038/ng.3283
Ernst J, Kellis M. Discovery and characterization of chromatin states for systematic annotation of the human genome. Nat Biotechnol. 2010;28:817.
pubmed: 20657582 pmcid: 2919626 doi: 10.1038/nbt.1662
Ernst J, Kheradpour P, Mikkelsen TS, Shoresh N, Ward LD, Epstein CB, et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature. 2011;473:43.
pubmed: 21441907 pmcid: 3088773 doi: 10.1038/nature09906
Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9:357–9.
pubmed: 22388286 pmcid: 3322381 doi: 10.1038/nmeth.1923
Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 2008;9:R137.
pubmed: 18798982 pmcid: 2592715 doi: 10.1186/gb-2008-9-9-r137
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.
pubmed: 25516281 pmcid: 4302049 doi: 10.1186/s13059-014-0550-8
Li Z, Schulz MH, Look T, Begemann M, Zenke M, Costa IG. Identification of transcription factor binding sites using ATAC-seq. Genome Biol. 2019;20:45.
pubmed: 30808370 pmcid: 6391789 doi: 10.1186/s13059-019-1642-2
Duren Z, Chen X, Jiang R, Wang Y, Wong WH. Modeling gene regulation from paired expression and chromatin accessibility data. Proc Natl Acad Sci USA. 2017;114:E4914–E23.
pubmed: 28576882 pmcid: 5488952 doi: 10.1073/pnas.1704553114
van de Geijn B, McVicker G, Gilad Y, Pritchard JK. WASP: allele-specific software for robust molecular quantitative trait locus discovery. Nat Methods. 2015;12:1061–3.
pubmed: 26366987 pmcid: 4626402 doi: 10.1038/nmeth.3582
Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46:310–5.
pubmed: 24487276 pmcid: 3992975 doi: 10.1038/ng.2892
McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, Lowe CB, et al. GREAT improves functional interpretation of cis-regulatory regions. Nat Biotechnol. 2010;28:495–501.
pubmed: 20436461 pmcid: 4840234 doi: 10.1038/nbt.1630
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545–50.
pubmed: 16199517 pmcid: 1239896 doi: 10.1073/pnas.0506580102
Mayran A, Sochodolsky K, Khetchoumian K, Harris J, Gauthier Y, Bemmo A, et al. Pioneer and nonpioneer factor cooperation drives lineage specific chromatin opening. Nat Commun. 2019;10:3807.
pubmed: 31444346 pmcid: 6707328 doi: 10.1038/s41467-019-11791-9
Tian L, Shao Y, Nance S, Dang J, Xu B, Ma X, et al. Long-read sequencing unveils IGH-DUX4 translocation into the silenced IGH allele in B-cell acute lymphoblastic leukemia. Nat Commun. 2019;10:2789.
pubmed: 31243274 pmcid: 6594946 doi: 10.1038/s41467-019-10637-8
Schmidl C, Klug M, Boeld TJ, Andreesen R, Hoffmann P, Edinger M, et al. Lineage-specific DNA methylation in T cells correlates with histone methylation and enhancer activity. Genome Res. 2009;19:1165–74.
pubmed: 19494038 pmcid: 2704427 doi: 10.1101/gr.091470.109
Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature. 2009;462:315–22.
pubmed: 19829295 pmcid: 2857523 doi: 10.1038/nature08514
Wiench M, John S, Baek S, Johnson TA, Sung MH, Escobar T, et al. DNA methylation status predicts cell type-specific enhancer activity. EMBO J. 2011;30:3028–39.
pubmed: 21701563 pmcid: 3160184 doi: 10.1038/emboj.2011.210
Nordlund J, Backlin CL, Wahlberg P, Busche S, Berglund EC, Eloranta ML, et al. Genome-wide signatures of differential DNA methylation in pediatric acute lymphoblastic leukemia. Genome Biol. 2013;14:r105.
pubmed: 24063430 pmcid: 4014804 doi: 10.1186/gb-2013-14-9-r105
Nordlund J, Backlin CL, Zachariadis V, Cavelier L, Dahlberg J, Ofverholm I, et al. DNA methylation-based subtype prediction for pediatric acute lymphoblastic leukemia. Clin Epigenet. 2015;7:11.
doi: 10.1186/s13148-014-0039-z
Thurman RE, Rynes E, Humbert R, Vierstra J, Maurano MT, Haugen E, et al. The accessible chromatin landscape of the human genome. Nature. 2012;489:75–82.
pubmed: 22955617 pmcid: 3721348 doi: 10.1038/nature11232
Tsompana M, Buck MJ. Chromatin accessibility: a window into the genome. Epigenet Chromatin. 2014;7:33.
doi: 10.1186/1756-8935-7-33
Busche S, Ge B, Vidal R, Spinella JF, Saillour V, Richer C, et al. Integration of high-resolution methylome and transcriptome analyses to dissect epigenomic changes in childhood acute lymphoblastic leukemia. Cancer Res. 2013;73:4323–36.
pubmed: 23722552 doi: 10.1158/0008-5472.CAN-12-4367
Neveu B, Spinella JF, Richer C, Lagacé K, Cassart P, Lajoie M, et al. CLIC5: a novel ETV6 target gene in childhood acute lymphoblastic leukemia. Haematologica. 2016;101:1534–43.
pubmed: 27540136 pmcid: 5479611 doi: 10.3324/haematol.2016.149740
Consortium GT. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45:580–5.
doi: 10.1038/ng.2653
Manolio TA. Genomewide association studies and assessment of the risk of disease. N Engl J Med. 2010;363:166–76.
pubmed: 20647212 doi: 10.1056/NEJMra0905980
Degner JF, Pai AA, Pique-Regi R, Veyrieras JB, Gaffney DJ, Pickrell JK, et al. DNase I sensitivity QTLs are a major determinant of human expression variation. Nature. 2012;482:390–4.
pubmed: 22307276 pmcid: 3501342 doi: 10.1038/nature10808
McVicker G, van de Geijn B, Degner JF, Cain CE, Banovich NE, Raj A, et al. Identification of genetic variants that affect histone modifications in human cells. Science. 2013;342:747–9.
pubmed: 24136359 pmcid: 3947669 doi: 10.1126/science.1242429
Sakabe NJ, Savic D, Nobrega MA. Transcriptional enhancers in development and disease. Genome Biol. 2012;13:238.
pubmed: 22269347 pmcid: 3334578 doi: 10.1186/gb-2012-13-1-238
Engel KL, Mackiewicz M, Hardigan AA, Myers RM, Savic D. Decoding transcriptional enhancers: evolving from annotation to functional interpretation. Semin Cell Dev Biol. 2016;57:40–50.
pubmed: 27224938 pmcid: 5018832 doi: 10.1016/j.semcdb.2016.05.014
Autry RJ, Paugh SW, Carter R, Shi L, Liu J, Ferguson DC, et al. Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. Nat Cancer. 2020;1:329–44.
pubmed: 32885175 pmcid: 7467080 doi: 10.1038/s43018-020-0037-3
Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013;339:957–9.
pubmed: 23348506 pmcid: 4423787 doi: 10.1126/science.1229259
Mansour MR, Abraham BJ, Anders L, Berezovskaya A, Gutierrez A, Durbin AD, et al. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science. 2014;346:1373–7.
pubmed: 25394790 pmcid: 4720521 doi: 10.1126/science.1259037
Melton C, Reuter JA, Spacek DV, Snyder M. Recurrent somatic mutations in regulatory regions of human cancer genomes. Nat Genet. 2015;47:710–6.
pubmed: 26053494 pmcid: 4485503 doi: 10.1038/ng.3332
Katainen R, Dave K, Pitkanen E, Palin K, Kivioja T, Valimaki N, et al. CTCF/cohesin-binding sites are frequently mutated in cancer. Nat Genet. 2015;47:818–21.
pubmed: 26053496 doi: 10.1038/ng.3335
Downing JR, Wilson RK, Zhang J, Mardis ER, Pui CH, Ding L, et al. The Pediatric Cancer Genome Project. Nat Genet. 2012;44:619–22.
pubmed: 22641210 pmcid: 3619412 doi: 10.1038/ng.2287
Sarvaiya PJ, Schwartz JR, Hernandez CP, Rodriguez PC, Vedeckis WV. Role of c-Myb in the survival of pre B-cell acute lymphoblastic leukemia and leukemogenesis. Am J Hematol. 2012;87:969–76.
pubmed: 22764095 pmcid: 3578739 doi: 10.1002/ajh.23283
Frolova O, Samudio I, Benito JM, Jacamo R, Kornblau SM, Markovic A, et al. Regulation of HIF-1alpha signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biol Ther. 2012;13:858–70.
pubmed: 22785211 pmcid: 3414410 doi: 10.4161/cbt.20838
Khan NI, Bradstock KF, Bendall LJ. Activation of Wnt/beta-catenin pathway mediates growth and survival in B-cell progenitor acute lymphoblastic leukaemia. Br J Haematol. 2007;138:338–48.
pubmed: 17614820 doi: 10.1111/j.1365-2141.2007.06667.x
Thiago LS, Costa ES, Lopes DV, Otazu IB, Nowill AE, Mendes FA, et al. The Wnt signaling pathway regulates Nalm-16 b-cell precursor acute lymphoblastic leukemic cell line survival and etoposide resistance. Biomed Pharmacother. 2010;64:63–72.
pubmed: 19864107 doi: 10.1016/j.biopha.2009.09.005
Kuhnl A, Gokbuget N, Kaiser M, Schlee C, Stroux A, Burmeister T, et al. Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemia. Blood. 2011;118:6362–7.
pubmed: 22010100 doi: 10.1182/blood-2011-04-350850
Gang EJ, Hsieh YT, Pham J, Zhao Y, Nguyen C, Huantes S, et al. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia. Oncogene. 2014;33:2169–78.
pubmed: 23728349 doi: 10.1038/onc.2013.169
Hogan LE, Meyer JA, Yang J, Wang J, Wong N, Yang W, et al. Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood. 2011;118:5218–26.
pubmed: 21921043 pmcid: 3217405 doi: 10.1182/blood-2011-04-345595
Maffei R, Bulgarelli J, Fiorcari S, Martinelli S, Castelli I, Valenti V, et al. Endothelin-1 promotes survival and chemoresistance in chronic lymphocytic leukemia B cells through ETA receptor. PLoS ONE. 2014;9:e98818.
pubmed: 24901342 pmcid: 4046988 doi: 10.1371/journal.pone.0098818
Zylbersztejn F, Flores-Violante M, Voeltzel T, Nicolini FE, Lefort S, Maguer-Satta V. The BMP pathway: a unique tool to decode the origin and progression of leukemia. Exp Hematol. 2018;61:36–44.
pubmed: 29477370 doi: 10.1016/j.exphem.2018.02.005
Hunger SP, Mullighan CG. Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. Blood . 2015;125:3977–87.
pubmed: 25999453 pmcid: 4481590 doi: 10.1182/blood-2015-02-580043

Auteurs

Jonathan D Diedrich (JD)

Hematological Malignancies Program and Center for Precision Medicine in Leukemia, St. Jude Children's Research Hospital, Memphis, TN, USA.
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.

Qian Dong (Q)

Hematological Malignancies Program and Center for Precision Medicine in Leukemia, St. Jude Children's Research Hospital, Memphis, TN, USA.
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.

Daniel C Ferguson (DC)

Hematological Malignancies Program and Center for Precision Medicine in Leukemia, St. Jude Children's Research Hospital, Memphis, TN, USA.
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.

Brennan P Bergeron (BP)

Hematological Malignancies Program and Center for Precision Medicine in Leukemia, St. Jude Children's Research Hospital, Memphis, TN, USA.
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Graduate School of Biomedical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.

Robert J Autry (RJ)

Hematological Malignancies Program and Center for Precision Medicine in Leukemia, St. Jude Children's Research Hospital, Memphis, TN, USA.
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Integrated Biomedical Sciences Program, University of Tennessee Health Science Center, Memphis, TN, USA.

Maoxiang Qian (M)

Hematological Malignancies Program and Center for Precision Medicine in Leukemia, St. Jude Children's Research Hospital, Memphis, TN, USA.
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.

Wenjian Yang (W)

Hematological Malignancies Program and Center for Precision Medicine in Leukemia, St. Jude Children's Research Hospital, Memphis, TN, USA.
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.

Colton Smith (C)

Hematological Malignancies Program and Center for Precision Medicine in Leukemia, St. Jude Children's Research Hospital, Memphis, TN, USA.
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.

James B Papizan (JB)

Department of Cell and Molecular biology and Center for Advanced Genome Engineering, St. Jude Children's Research Hospital, Memphis, TN, USA.

Jon P Connelly (JP)

Department of Cell and Molecular biology and Center for Advanced Genome Engineering, St. Jude Children's Research Hospital, Memphis, TN, USA.

Kohei Hagiwara (K)

Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.

Kristine R Crews (KR)

Hematological Malignancies Program and Center for Precision Medicine in Leukemia, St. Jude Children's Research Hospital, Memphis, TN, USA.
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.

Shondra M Pruett-Miller (SM)

Department of Cell and Molecular biology and Center for Advanced Genome Engineering, St. Jude Children's Research Hospital, Memphis, TN, USA.

Ching-Hon Pui (CH)

Hematological Malignancies Program and Center for Precision Medicine in Leukemia, St. Jude Children's Research Hospital, Memphis, TN, USA.
Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.

Jun J Yang (JJ)

Hematological Malignancies Program and Center for Precision Medicine in Leukemia, St. Jude Children's Research Hospital, Memphis, TN, USA.
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.

Mary V Relling (MV)

Hematological Malignancies Program and Center for Precision Medicine in Leukemia, St. Jude Children's Research Hospital, Memphis, TN, USA.
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.

William E Evans (WE)

Hematological Malignancies Program and Center for Precision Medicine in Leukemia, St. Jude Children's Research Hospital, Memphis, TN, USA.
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.

Daniel Savic (D)

Hematological Malignancies Program and Center for Precision Medicine in Leukemia, St. Jude Children's Research Hospital, Memphis, TN, USA. daniel.savic@stjude.org.
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA. daniel.savic@stjude.org.
Integrated Biomedical Sciences Program, University of Tennessee Health Science Center, Memphis, TN, USA. daniel.savic@stjude.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH